The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a clinical study titled ‘A Multicenter, ...

"These three-year data show that raising the bar in atopic dermatitis treatment to long-term total skin clearance was an achievable treatment goal for at least half of EBGLYSS Week 16 responders, ...

European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy. Patient preferences ...

Please provide your email address to receive an email when new articles are posted on . Pediatric patients treated with nemolizumab saw a statistically significant improvement in pruritus. Nemolizumab ...

Nektar Therapeutics NKTR reported a loss of $1.87 per share for the third quarter of 2025, narrower than the Zacks Consensus ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three ...

Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment of atopic dermatitis in adolescents and adults, according to a phase 3 study.

HC Wainwright has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS). Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK ...

Efficacy of the investigational drug lebrikizumab is maintained in patients with moderate to severe atopic dermatitis for at least 1 year, according to new results from the phase 3 ADvocate1 and ...

MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 ...